Paroxetine controlled release compositions

Details Paroxetine controlled release compositions Paroxetine controlled release compositions

2007-06-12

2007-06-12

Sheikh, Humera N. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S465000, C424S468000, C424S472000, C424S474000, C424S482000

Reexamination Certificate

active

10024858

ABSTRACT:
A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

REFERENCES:
patent: 3536809 (1970-10-01), Appleweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3630200 (1971-12-01), Higuchi
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4007196 (1977-02-01), Christensen et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 4085225 (1978-04-01), Welle et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4444778 (1984-04-01), Coughlin
patent: 4536518 (1985-08-01), Welch, Jr. et al.
patent: 4615697 (1986-10-01), Robinson
patent: 4721723 (1988-01-01), Barnes et al.
patent: 4797286 (1989-01-01), Thakkar et al.
patent: 4804669 (1989-02-01), Lassen
patent: 4839177 (1989-06-01), Colombo et al.
patent: 4847092 (1989-07-01), Thakkar et al.
patent: 4851228 (1989-07-01), Zentner et al.
patent: 4988679 (1991-01-01), Chavkin et al.
patent: 4996358 (1991-02-01), Handa et al.
patent: 5102666 (1992-04-01), Acharya
patent: 5110605 (1992-05-01), Acharya
patent: 5151434 (1992-09-01), Irikura et al.
patent: 5271946 (1993-12-01), Hettche
patent: 5284662 (1994-02-01), Koparkar et al.
patent: 5322697 (1994-06-01), Meyer
patent: 5371092 (1994-12-01), Johnson
patent: 5422123 (1995-06-01), Conte et al.
patent: 5668134 (1997-09-01), Limstra et al.
patent: 5686094 (1997-11-01), Acharya
patent: 5776969 (1998-07-01), James
patent: 5811436 (1998-09-01), Leonard et al.
patent: 6133289 (2000-10-01), Ward et al.
patent: 6168805 (2001-01-01), Hein et al.
patent: 2 031 393 (1989-12-01), None
patent: 1 298 479 (1992-04-01), None
patent: 2 143 070 (2001-12-01), None
patent: 0 269 303 (1987-11-01), None
patent: 0 449 562 (1991-03-01), None
patent: 0 432 607 (1991-06-01), None
patent: 0 546 593 (1992-10-01), None
patent: 0 654 263 (1994-11-01), None
patent: 0 714 663 (1996-06-01), None
patent: 4 036 237 (1992-02-01), None
patent: 5 139 964 (1993-06-01), None
patent: WO 91/13612 (1991-09-01), None
patent: WO 92/03124 (1992-03-01), None
patent: 92/09281 (1992-06-01), None
patent: WO 92/13452 (1992-08-01), None
patent: WO 92/19226 (1992-11-01), None
patent: WO 93/09769 (1993-05-01), None
patent: WO 93/24154 (1993-12-01), None
patent: WO 94/10990 (1994-05-01), None
patent: 95/15155 (1995-06-01), None
patent: WO 95/16448 (1995-06-01), None
patent: WO 95/19956 (1995-07-01), None
patent: WO 95/20964 (1995-08-01), None
patent: WO 95/30422 (1995-11-01), None
patent: WO 96/02240 (1996-02-01), None
patent: WO 96/14059 (1996-05-01), None
patent: WO 96/31197 (1996-10-01), None
patent: WO 96/33165 (1996-10-01), None
patent: WO 96/33166 (1996-10-01), None
patent: WO 97/02037 (1997-01-01), None
patent: WO 97/02239 (1997-01-01), None
patent: WO 97/03966 (1997-02-01), None
patent: WO 97/18798 (1997-05-01), None
patent: WO 97/26257 (1997-07-01), None
patent: WO 97/43249 (1997-11-01), None
patent: WO 98/43959 (1998-10-01), None
Chemical Abstracts, 124(10), Abstract No. 127144, XP002018196 (1996), See Abstract and CA, A2143070 (P.MODI) (1995).
Rickels, et al., J. Clin. Psychiatry, vol. 51(12) Suppl. B (1990).
Willner, Psychopharmacology, vol. 85, pp. 387-404 (1985).
Drug Facts and Compounds, pp. 1325, 1994 Edition.
Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Cover Page and pp. 1676 to 1686 of Chapter 91 (1990).
Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Company, Cover Page and pp. 1660, 1662, 1664 and 1665 of Chapter 94 Date?.
Caley, et al., The Annals of Pharmacology, 1993, vol. 27, pp. 1212-1222.
FDA FOIA Materials, Jun. 1993.
Lund, et al., Acta. Pharmacol. Toxicol., 1979, vol. 44, pp. 289-295.
Torii, et al., Naunyn-Schmiedeberg's Arch. Pharmacol., 1991, vol. 344, pp. 564-567.
Gale, J. of Pediatric Gast. and Nutrition, 1995, vol. 21, Suppl. 1, pp. S22-S28.
Bailey, et al., J. of Psychopharm., 1995, vol. 9, No. 2, pp. 137-141.
Finley, The Annals of Pharmacotherapy, 1994, vol. 28, pp. 1359-1369.
J. van Harten, et al., Neuropsychopharmacology, 1994, vol. 10, No. 35, pp. 104S.
Chambers Science and Technology Dictionary, 1994.
Duboff, J. Clin. Psychopharmacology, 1993, vol. 13, No. 6, pp. 28S-33S.
Conte, et al., Travaux Originaux Reserach Papers, Sep. 1993.
Conte, et al., J. of Controlled Release, 1993, vol. 26, pp. 39-47.
Harten, et al., Clin. Pharmacokinet, 1993, vol. 24, No. 2, pp. 177-182.
Bergeron, et al., Am. J. Psychiatry, 1994, vol. 151, No. 7, pp. 1084-1086.
Dunner, et al., J. Clin. Psychiatry, 1992, vol. 53, No. 2, pp. 21-22.
Golden, Psychoopharmacology Bulletin, 2003, vol. 37, Supp. 1, pp. 176-186.
Turkish Application No. TR99/317, Examination Report (translation) 1980.
Opposition to Israeli Appl. No. 122940, Unipharm LTD v. SmithKline Beecham, Jan. 2002.
Remington's Pharma Sciences, Editorial Panamerica Co., 1980 (17thedition)-(translation).
Opposition to European Patent No. EP 0839039, (Aug. 5, 2004) by Solvay Pharmaceuticals, Netherlands.
Opposition to European Patent No. EP 0839039. (Aug. 4, 2004) by Dragotti & Associati SRL, Italy.
Aulton, Ed., “Pharmaceutics: The Science of Dosage form Design”, pp. 204-211, Churchill Livingstone, Edinburgh (1998).
Leonard;J Clin Psychiatry, 1993 Aug; 54 Suppl: 3-15; discussion.
Leonard:Drugs 1992; 43 Suppl 2:3-9; discussion 9-10.
Jenner;Int Clin Psychopharmacol. 1992 Jun.; 6 Suppl 4: pp. 69-80.
De Wilde et al.,Acta Psychiatr Scand. 1993 Feb; 87(2): pp. 141-5.
Boyer & Feighner;J Clin Psychiatry, 1992 Feb; 53 Suppl: pp. 3-6.
Dechant & Clissold;Drugs 1991 Feb; 41(2): pp. 225-53.
Lucchelli et al.,Br J Pharmacol., 1995 Mar; 114(5): pp. 1017-25.
Sanger & McClelland;Eur J Pharmacol. 1986 Aug 15: 127(3): pp. 179-85.
Chambliss et al.,J Pharma Sci. 1984 Sep; 73(9): pp. 1215-9.
Ryan et al.,Clin Pharmacol Ther. 1987 Jul; 42(1): pp. 28-32.
Hawthorne et al.,Br J Clin Pharmacol. 1991 Jul; 32(1): pp. 77-83.
Aabakken et al.,Scand J Gastroenterol Suppl. 1989; 163: pp. 65-73.
Florence & Jani;Drug Saf. 1994 Mara; 10(3): pp. 233-66.
Mori et al.,J Pharm Sci 1991 Sep; 80(9): pp. 876-80.
Lucker et al.,Arzneimittelforschung. 1982; 32(4): pp. 409-13.
Fara et al.,Pharm Res. 1988 Mar; 5(3): pp. 165-71.
Perucca et al, Clin Pharmacokinet (1994) 27(3): pp. 175-190.
ABPI Data Sheet Compendium 1988-89, pp. 445-6.
Freeman, J Psychiatr Neurosci, vol. 16 No. 2 (Suppl 1), 1991.
Synopsis section of Clinical Trials, Apr. 06, 1998, pp. 1-11.
Synopsis section of Clinical Trials, Dec. 03, 1997, pp. 1-9.
Synopsis section of Clinical Trials, Dec. 04, 1997, pp. 1-9.
Opposition to European Patent No. EP-B-0839039 dated Aug. 4, 2006.
Lee & Robinson, 1978, Chapter 3 “Methods to achieve sustained drug delivery”, pp. 150 and 176-178.
Remington: The Science and Practice of Pharmacy, vol. II, 1995, Chapter 71, pp. 1189-1195.
Remington: The Science and Practice of Pharmacy, vol. II, 1995, Chapter 94, pp. 1660-1675.
Final Clinical Report 29060/451, Mar. 18, 1996, pp. 1-42.
Final Clinical Report 29060/474, Oct. 17, 1997, pp. 1-48.
Final Clinical Report 29060/452, Apr. 17, 1996, pp. I-XVIII, 1-34 and 171-182.
Rapaport, et al., J. Clin. Psychiatry, 2003, vol. 64, pp. 1065-1074.
Golden, et al., J. Clin. Psychiatry, 2002, vol. 63, pp. 577-584.
DeVane, J. Clin. Psychiatry, 2003, vol. 64, Suppl. 18, pp. 14-19.
Nemeroff, J. Clin. Psychiatry, 2003, vol. 64, Suppl. 18, p. 25-30.

Affiliated with

Also associated with

Rating

Paroxetine controlled release compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Paroxetine controlled release compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Paroxetine controlled release compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3823845